Latest Articles

Publication Date
Presacral Clear Cell Carcinoma of Müllerian Origin 20 Years After Hysterectomy and Bilateral Salpingo-Oophorectomy: A Case Report and Literature Review.

Primary presacral clear cell carcinoma (CCC) of Müllerian origin is extremely rare. Malignant transformation of endometriosis is a known phenomenon, though typically involving the ovaries or pelvic peritoneum. Retroperitoneal presentation, …

Published: Nov. 7, 2025, midnight
Misleading Lesions in Gynecological Malignancies: A Case Report of Desmoid Tumor During Pregnancy and a Narrative Review of the Literature.

Background: Desmoid tumors (DTs) are rare, locally aggressive soft-tissue neoplasms that often affect women of reproductive age. Pregnancy and prior abdominal surgery or trauma have been associated with tumor development …

Published: Nov. 3, 2025, midnight
Shaoyao Gancao Decoction: a comprehensive review of modern clinical applications and underlying pharmacological mechanisms.

Shaoyao Gancao Decoction, a classic formula from Zhang Zhongjing in the Han Dynasty, has the effects of regulating the function of the liver, relieving spasm and stopping pain. Traditionally, it …

Published: Oct. 20, 2025, midnight
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 4:49 p.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - BIOENGINEER.ORG

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival BIOENGINEER.ORG

Published: Oct. 14, 2025, 4:49 p.m.
Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials - BMC Cancer

Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials BMC Cancer

Published: Oct. 14, 2025, 2:41 p.m.
Ovarian reserve and stimulation response before chemotherapy treatment in breast cancer patients undergoing fertility preservation: a historical cohort study.

Fertility preservation is an important aspect of care for breast cancer patients. This study was designed to compare the ovarian function including ovarian reserve and ovarian stimulation response in breast …

Published: Oct. 14, 2025, midnight
Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer - CancerNetwork

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer CancerNetwork

Published: Oct. 13, 2025, 10:05 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!